您要查找的是不是:
- platelet survival time 血小板存活時間
- The aver age survival time was 6 months. 平均生存時間為6個月。
- It can prolong mouse s survival time in hypoxia. 醒神液能延長小鼠耐缺氧存活時間。
- The median survival time for the entire sample was 34 months. 二年及五年的存活率各為65%25及25%25。
- The Prediction of the Survival Time about Hepatoma Patients with the BP Neural Network Method. BP神經網路預測肝癌患者生存期的研究。
- The overall response rate was 73.5% with a CR rate of 17.6% .Median survival time was 9.5 months. 治療總有效率為73.;5%25,其中完全緩解率為17
- The average survival time was prolonged but the rate of death protection was lower than that of Virazole group. 但死亡保護率低於病毒唑。
- Survival time and complete remission duration(CRD) were evaluated using Kaplan-Meier method. Kaplan -Meier方法評價兩組生存期和緩解期 ;
- In addition,the survival time was increased to 75%in CQ group and to 70% in DXM group. 此外,PLA2抑製劑可使家兔8h存活率由48%25提高到75%25(CQ組)和70%25(DXM組)。
- Asarinin could prolong the survival time of allografts,which was similar to CsA group(P>0.05). 移植心存活時間;CsA組、細辛脂素組和混合藥物組均較陽性對照組顯著延長(P<0.;01)。
- DRC treatment prolonged the survival time of mice and the duration of electrocardiograph in trachea closed mice. 實驗結果表明:DRC能顯著延長小鼠常壓缺氧環境下的存活時間以及夾閉氣管小鼠心電圖消失時間;
- The survival time in BPI group was significantly higher than in physiological saline (PS) group. BPI治療組動物存活時間明顯長於生理鹽水組 ;
- PAP increased, survival time is shorttcr and MDA content increased after L-NNA infusion. 注入L-NNA后顯著增加了休克后PAP,縮短了存活時間,並使血中MDA含量明顯增加。
- Tumor antigen specific CTLs may prevent metastasis in the LCI-D20 model and prolong the survival time. 腫瘤抗原特異性CTL可以預防LCI-D20模型肝癌發生轉移,延長動物存活時間。
- Median survival time(MST)was 10 months. Median time to progression (MTTP) was 8 months. 中位生存時間(MST)為10個月,中位進展時間(MTTP)為8個月。
- The prognoses of these patients are extremely poor with a mean survival time of only 7.6 weeks. 這些病人的預后很差,平均存活時間只有7.;6周。
- The algorithm is applied to an example involving data for survival time for carcinoma of the oropharynx. 該演算法應用於一個涉及口咽癌患者生存時間數據的例子。
- MSI-positive patients had significantly shorter survival time than MSI-negative ones had (P=0.0001). MSI陽性患者的生存時間顯著地低於MSI陰性患者(P=0.;0001)。
- Onders, noting that axonal sprouting will likely afford patients the longest survival time. 神經軸分枝似乎可以提供與患者最長的存活期。
- IHC analysis showed survival time were shorter in the high ki-67 group than in the low group(P<0.05). 臨床資料單因素分析顯示,臨床分期、結外侵犯情況、ECOG評分、血清乳酸脫氫酶水平及療效均為瀰漫大B細胞淋巴瘤的獨立預后因素(P<0.;05),是否合併放療或使用美羅華對預后影響無統計學差別;